EP1553955A4 - Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines - Google Patents

Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines

Info

Publication number
EP1553955A4
EP1553955A4 EP03756864A EP03756864A EP1553955A4 EP 1553955 A4 EP1553955 A4 EP 1553955A4 EP 03756864 A EP03756864 A EP 03756864A EP 03756864 A EP03756864 A EP 03756864A EP 1553955 A4 EP1553955 A4 EP 1553955A4
Authority
EP
European Patent Office
Prior art keywords
reagents
diseases
treatment
methods
disorders associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03756864A
Other languages
German (de)
French (fr)
Other versions
EP1553955A2 (en
Inventor
Edward Roydon Jost-Price
Palaniyandi Manivasakam
Brendan Smith
Jason Fong
Benjamin A Auspitz
M James Nichols
Curtis Keith
Grant R Zimmermann
Bradley B Brasher
Noah Sachs
Todd W Chappell
Daniel Grau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zalicus Inc
Original Assignee
CombinatoRx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32074779&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1553955(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by CombinatoRx Inc filed Critical CombinatoRx Inc
Publication of EP1553955A2 publication Critical patent/EP1553955A2/en
Publication of EP1553955A4 publication Critical patent/EP1553955A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP03756864A 2002-09-24 2003-09-24 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines Withdrawn EP1553955A4 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US41304002P 2002-09-24 2002-09-24
US413040P 2002-09-24
US41726102P 2002-10-09 2002-10-09
US417261P 2002-10-09
US42742402P 2002-11-19 2002-11-19
US42752602P 2002-11-19 2002-11-19
US427526P 2002-11-19
US427424P 2002-11-19
US46475303P 2003-04-23 2003-04-23
US464753P 2003-04-23
PCT/US2003/030156 WO2004030618A2 (en) 2002-09-24 2003-09-24 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines

Publications (2)

Publication Number Publication Date
EP1553955A2 EP1553955A2 (en) 2005-07-20
EP1553955A4 true EP1553955A4 (en) 2008-11-05

Family

ID=32074779

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03756864A Withdrawn EP1553955A4 (en) 2002-09-24 2003-09-24 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines

Country Status (12)

Country Link
EP (1) EP1553955A4 (en)
JP (1) JP2006503905A (en)
AR (1) AR041386A1 (en)
AU (1) AU2003299196A1 (en)
BR (1) BR0314713A (en)
CA (1) CA2509526A1 (en)
HR (1) HRP20050355A2 (en)
IS (1) IS7811A (en)
MX (1) MXPA05003152A (en)
NO (1) NO20051669L (en)
TW (1) TW200422042A (en)
WO (1) WO2004030618A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1599212A4 (en) * 2003-02-14 2006-02-08 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
CA2538023A1 (en) * 2003-09-24 2005-04-07 Combinatorx, Incorporated Therapeutic regimens for administering drug combinations
CN1980649A (en) * 2004-05-17 2007-06-13 康宾纳特克斯公司 Methods and reagents for the treatment of immunoinflammatory disorders
MX2007006045A (en) * 2004-11-19 2007-06-13 Organon Nv Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression.
AU2011236053B2 (en) * 2004-11-19 2014-06-26 Merck Sharpe & Dohme B.V. Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression
SI1719507T1 (en) * 2005-04-13 2010-11-30 Astion Dev As Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
JP4832806B2 (en) * 2005-06-03 2011-12-07 久光製薬株式会社 Transdermal formulation
TW200711649A (en) * 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
WO2008031014A1 (en) * 2006-09-08 2008-03-13 Ore Pharmaceuticals Inc. Method for reducing or alleviating inflammation in the digestive tract
US20080064709A1 (en) * 2006-09-11 2008-03-13 Duke University Methods and compositions for the treatment of vascular depression
GB0701171D0 (en) * 2007-01-22 2007-02-28 Imp Innovations Ltd Compositions and uses thereof
WO2010098230A1 (en) * 2009-02-27 2010-09-02 久光製薬株式会社 Transdermal preparation
PT117765A (en) * 2022-01-28 2023-07-28 Faculdade De Farmacia Da Univ De Lisboa TOPICAL FORMULATION OF FLUVOXAMINE FOR THE TREATMENT OF PSORIASIS
WO2024074699A1 (en) * 2022-10-07 2024-04-11 Oculis Operations Sarl Eye drop microsuspensions of mtor inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002169A2 (en) * 1996-07-15 1998-01-22 Alza Corporation Novel formulations for the administration of fluoxetine
US6281248B1 (en) * 2000-02-16 2001-08-28 Magda Abdel Fattah Ahmed Composition for treating asthma
WO2002043652A2 (en) * 2000-11-29 2002-06-06 Ramot At Tel-Aviv University Ltd. Anti-proliferative drugs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU674292B2 (en) * 1991-10-15 1996-12-19 Immunex Corporation Methods and compositions for treating allergic reactions
GB9603137D0 (en) * 1996-02-15 1996-04-17 Merck Sharp & Dohme Therapeutic agents
BR9810409A (en) * 1997-03-18 2000-08-22 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002169A2 (en) * 1996-07-15 1998-01-22 Alza Corporation Novel formulations for the administration of fluoxetine
US6281248B1 (en) * 2000-02-16 2001-08-28 Magda Abdel Fattah Ahmed Composition for treating asthma
WO2002043652A2 (en) * 2000-11-29 2002-06-06 Ramot At Tel-Aviv University Ltd. Anti-proliferative drugs

Also Published As

Publication number Publication date
HRP20050355A2 (en) 2005-10-31
MXPA05003152A (en) 2006-04-27
AU2003299196A1 (en) 2004-04-23
IS7811A (en) 2005-04-19
BR0314713A (en) 2005-07-26
EP1553955A2 (en) 2005-07-20
AR041386A1 (en) 2005-05-18
WO2004030618A3 (en) 2005-04-07
CA2509526A1 (en) 2004-04-15
WO2004030618A2 (en) 2004-04-15
TW200422042A (en) 2004-11-01
JP2006503905A (en) 2006-02-02
NO20051669L (en) 2005-06-10

Similar Documents

Publication Publication Date Title
ZA200601973B (en) Methods and reagents for the treatment of immuno-inflammatory disorders
IL174918A0 (en) Methods and reagents for the treatment of immunoinflammatory disorders
AU2003286567A8 (en) Methods for the treatment of skin disorders
IL210090A0 (en) TREATMENT OF TNFa RELATED DISORDERS
HK1152243A1 (en) Vegf for use in the treatment of central nervous system disorders vegf
EP1509279A4 (en) Device and method for the treatment of cardiac disorders
PL372425A1 (en) Dihydrobenzodiazepin-2-one-derivatives for the treatment of neurological disorders
AU2003233583A8 (en) Oral lactoferrin in the treatment of respiratory disorders
AU2003286611A8 (en) Cytomodulating peptides and methods for treating neurological disorders
EP1755654A4 (en) Methods and systems for treatment of neurological diseases of the central nervous system
HK1092367A1 (en) Combination therapy for the treatment of ocular neovascular disorders
IL175610A0 (en) Methods and reagents for the treatment of inflammatory disorders
EP1450837A4 (en) Interleukin-1 receptors in the treatment of diseases
AU2003249983A8 (en) Piperidines useful for the treatment of central nervous system disorders
AU2003285091A8 (en) Interferon antagonists useful for the treatment of interferon related diseases
HK1203216A1 (en) Materials and methods for treating disorders of the ear
EP1553955A4 (en) Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
EP1499309A4 (en) Prevention and treatment of functional somatic disorders, including stress-related disorders
IL183656A0 (en) Indenyl derivatives and use thereof for the treatment of neurological disorders
EP1536834A4 (en) Design of chemokine analogs for the treatment of human diseases
EP1416957A4 (en) Treatment of immune disorders and b cell disorders
AU2003293099A8 (en) Treatment of dna damage related disorders
PL371281A1 (en) Methods and compositions for the treatment of eye diseases
GB0128674D0 (en) Treatment of sleep disorders and the like
AU2003259246A8 (en) Methods for the use of neurotoxin in the treatment of urologic disorders

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050422

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GRAU, DANIEL

Inventor name: CHAPPELL, TODD W.

Inventor name: SACHS, NOAH

Inventor name: BRASHER, BRADLEY B.

Inventor name: ZIMMERMANN, GRANT R.

Inventor name: KEITH, CURTIS

Inventor name: NICHOLS, M. JAMES

Inventor name: AUSPITZ, BENJAMIN A.

Inventor name: FONG, JASON

Inventor name: SMITH, BRENDAN

Inventor name: MANIVASAKAM, PALANIYANDI

Inventor name: JOST-PRICE, EDWARD ROYDON

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GRAU, DANIEL

Inventor name: CHAPPELL, TODD W.

Inventor name: SACHS, NOAH

Inventor name: BRASHER, BRADLEY B.

Inventor name: ZIMMERMANN, GRANT R.

Inventor name: KEITH, CURTIS

Inventor name: NICHOLS, M. JAMES

Inventor name: AUSPITZ, BENJAMIN A.

Inventor name: FONG, JASON

Inventor name: SMITH, BRENDAN

Inventor name: MANIVASAKAM, PALANIYANDI

Inventor name: JOST-PRICE, EDWARD ROYDON

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GRAU, DANIEL

Inventor name: CHAPPELL, TODD W.

Inventor name: SACHS, NOAH

Inventor name: BRASHER, BRADLEY B.

Inventor name: ZIMMERMANN, GRANT R.

Inventor name: KEITH, CURTIS

Inventor name: NICHOLS, M. JAMES

Inventor name: AUSPITZ, BENJAMIN A.

Inventor name: FONG, JASON

Inventor name: SMITH, BRENDAN

Inventor name: MANIVASAKAM, PALANIYANDI

Inventor name: JOST-PRICE, EDWARD ROYDON

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: COMBINATORX, INCORPORATED

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: COMBINATORX, INCORPORATED

A4 Supplementary search report drawn up and despatched

Effective date: 20081007

17Q First examination report despatched

Effective date: 20100215

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100331